Shalby Ltd

Shalby Earnings Call: Key Takeaways

Shalby Limited reported Q4 FY26 consolidated revenue growth of 9.4% YoY. Key focus on MedTech turnaround with positive EBITDA and expansion in oncology services.

Shalby Earnings Call: Key Takeaways

Shalby delivered strong Q4 growth with EBITDA up 43.1% YoY, driven by operational efficiency and recovery in the implant business despite geopolitical headwinds in international segments.

Shalby Other Announcement

Shalby Limited corrected a typographical error regarding its Cost Auditor firm appointment for FY 2026-27. S A & Associates replaces the previously mentioned firm.

Execution

FY 2026-27

Shalby Earnings Call: Key Takeaways

Shalby Limited reports Q4 FY26 consolidated revenue growth of 9.4% YoY. The company is scaling its MedTech implant business and expanding hospital capacity through an asset-light O&M model.

Shalby Earnings Call: Key Takeaways

Shalby Limited delivered Q4 FY26 consolidated revenue growth of 9.4% YoY. Strategy focuses on diversifying specialties beyond arthroplasty and expanding the MedTech implant business.

Shalby Employee Stock Options

Shalby Limited granted 4,000 ESOPs at an exercise price of ₹100 per option. This long-term incentive plan aligns employee interests with shareholder value creation.

Value

₹0.04 Cr

Execution

2 year vesting; 1 year exercise

Shalby Q4 FY26 Results: Turns Profitable, Net Profit ₹18.5 Cr

Shalby Ltd reported revenue from operations of ₹287.4 Cr (+8.5% YoY) and net profit of ₹18.5 Cr for Q4 FY26.

Key figure

Net profit ₹18.5 Cr

Shalby Financial Results

Shalby Ltd reported audited FY2026 standalone revenue of ₹8,985.58 Million. The board did not recommend a dividend and appointed new cost auditors for FY2027.

Shalby Merger & Restructuring

Shalby Limited's step-down subsidiary, Ningen Lifecare, has been struck-off by the MCA. The non-operational entity's closure has no material financial impact on company operations.